GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nxera Pharma Co Ltd (FRA:JSS) » Definitions » Shiller PE Ratio

Nxera Pharma Co (FRA:JSS) Shiller PE Ratio : (As of May. 08, 2024)


View and export this data going back to 2019. Start your Free Trial

What is Nxera Pharma Co Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Nxera Pharma Co Shiller PE Ratio Historical Data

The historical data trend for Nxera Pharma Co's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nxera Pharma Co Shiller PE Ratio Chart

Nxera Pharma Co Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 509.87 204.11 180.19 -

Nxera Pharma Co Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 180.19 301.54 205.73 - -

Competitive Comparison of Nxera Pharma Co's Shiller PE Ratio

For the Biotechnology subindustry, Nxera Pharma Co's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nxera Pharma Co's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Nxera Pharma Co's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Nxera Pharma Co's Shiller PE Ratio falls into.



Nxera Pharma Co Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Nxera Pharma Co's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Nxera Pharma Co's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-0.014/106.8000*106.8000
=-0.014

Current CPI (Dec. 2023) = 106.8000.

Nxera Pharma Co Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 0.080 95.700 0.089
201406 -0.014 98.000 -0.015
201409 0.017 98.500 0.018
201412 0.029 97.900 0.032
201503 0.035 97.900 0.038
201506 -0.125 98.400 -0.136
201509 -0.023 98.500 -0.025
201512 0.376 98.100 0.409
201603 -0.477 97.900 -0.520
201606 1.389 98.100 1.512
201609 -0.056 98.000 -0.061
201612 0.007 98.400 0.008
201703 -0.110 98.100 -0.120
201706 0.035 98.500 0.038
201709 -0.108 98.800 -0.117
201712 -0.128 99.400 -0.138
201803 -0.097 99.200 -0.104
201806 -0.160 99.200 -0.172
201809 -0.208 99.900 -0.222
201812 -0.272 99.700 -0.291
201903 0.106 99.700 0.114
201906 -0.067 99.800 -0.072
201909 0.116 100.100 0.124
201912 -0.003 100.500 -0.003
202003 -0.081 100.300 -0.086
202006 -0.147 99.900 -0.157
202009 0.047 99.900 0.050
202012 0.314 99.300 0.338
202103 -0.110 99.900 -0.118
202106 -0.106 99.500 -0.114
202109 0.044 100.100 0.047
202112 0.271 100.100 0.289
202203 -0.194 101.100 -0.205
202206 -0.127 101.800 -0.133
202209 0.027 103.100 0.028
202212 0.308 104.100 0.316
202303 -0.120 104.400 -0.123
202306 -0.052 105.200 -0.053
202309 -0.379 106.200 -0.381
202312 -0.014 106.800 -0.014

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Nxera Pharma Co  (FRA:JSS) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Nxera Pharma Co Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Nxera Pharma Co's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Nxera Pharma Co (FRA:JSS) Business Description

Traded in Other Exchanges
Address
2-1 Kojimachi, Chiyoda-ku, PMO Hanzomon 11th Floor, Tokyo, JPN, 102-0083
Sosei Group Corp is an international biopharmaceutical company that develops treatments for a wide range of illnesses. The company utilizes its peptide platform technologies and nanotechnology to develop its product pipeline. Sosei actively seeks partnerships to aid its product development. The company's strategy for commercializing its therapies include utilizing its subsidiaries' drug discovery technologies, supplying technology to other companies, developing products in-house, and product licensing.

Nxera Pharma Co (FRA:JSS) Headlines

No Headlines